binding conformation
Recently Published Documents


TOTAL DOCUMENTS

69
(FIVE YEARS 4)

H-INDEX

21
(FIVE YEARS 0)

2021 ◽  
pp. 100698
Author(s):  
Yasuyuki Matoba ◽  
Yuichiro Sato ◽  
Kosuke Oda ◽  
Yuta Hatori ◽  
Kinjiro Morimoto

2021 ◽  
Author(s):  
Karina de Paula ◽  
Jademilson C. Santos ◽  
Ana Carolina Mafud ◽  
Alessandro S. Nascimento

AbstractDiabetes is an important chronic disease affecting about 10% of the adult population in the US and over 420 million people worldwide, resulting in 1.6 million deaths every year, according to the World Health Organization. The most common type of the disease, type 2 diabetes, can be pharmacologically managed using oral hypoglycemic agents or thiazolidinediones (TZDs), such as pioglitazone, which act by activating the Peroxisome Proliferated-Activated Receptor γ. Despite their beneficial effects in diabetes treatment, TZDs like rosiglitazone and troglitazone were withdrawn due to safety reasons, creating a void in the pharmacological options for the treatment of this important disease. Here, we explored a structure-based approach in the screening for new chemical probes for a deeper investigation of the effects of PPARγ activation. A class of tetrazole compounds was identified and the compounds named T1, T2 and T3 were purchased and evaluated for their ability to interact with the PPARγ ligand binding domain (LBD). The compounds were binders with micromolar range affinity, as determined by their IC50 values. A Monte Carlo simulation of the compound T2 revealed that the tetrazole ring makes favorable interaction with the polar arm of the receptor binding pocket. Finally, the crystal structure of the PPARγ-LBD-T2 complex was solved at 2.3 Å, confirming the binding mode for this compound. The structure also revealed that, when the helix H12 is mispositioned, an alternative binding conformation is observed for the ligand suggesting an H12-dependent binding conformation for the tetrazole compound.


RSC Advances ◽  
2021 ◽  
Vol 11 (20) ◽  
pp. 12036-12042
Author(s):  
Yao Liu ◽  
Yalong Cong ◽  
Chuanxi Zhang ◽  
Bohuan Fang ◽  
Yue Pan ◽  
...  

A rational design strategy was proposed to improve the efficient utilization of alternative biomimetic cofactor by P450 BM3 enzyme.


2018 ◽  
Vol 293 (41) ◽  
pp. 15765-15776 ◽  
Author(s):  
Linda M. Haugaard-Kedström ◽  
Han Siean Lee ◽  
Maryon V. Jones ◽  
Angela Song ◽  
Vishaal Rathod ◽  
...  

The neuropeptide relaxin-3 and its receptor relaxin family peptide receptor-3 (RXFP3) play key roles in modulating behavior such as memory and learning, food intake, and reward seeking. A linear relaxin-3 antagonist (R3 B1-22R) based on a modified and truncated relaxin-3 B-chain was recently developed. R3 B1-22R is unstructured in solution; thus, the binding conformation and determinants of receptor binding are unclear. Here, we have designed, chemically synthesized, and pharmacologically characterized more than 60 analogues of R3 B1-22R to develop an extensive understanding of its structure–activity relationships. We show that the key driver for affinity is the nonnative C-terminal Arg23. Additional contributors to binding include amino acid residues that are important also for relaxin-3 binding, including Arg12, Ile15, and Ile19. Intriguingly, amino acid residues that are not exposed in native relaxin-3, including Phe14 and Ala17, also interact with RXFP3. We show that R3 B1-22R has a propensity to form a helical structure, and modifications that support a helical conformation are functionally well-tolerated, whereas helix breakers such as proline residues disrupt binding. These data suggest that the peptide adopts a helical conformation, like relaxin-3, upon binding to RXFP3, but that its smaller size allows it to penetrate deeper into the orthosteric binding site, creating more extensive contacts with the receptor.


2017 ◽  
Vol 13 (2) ◽  
pp. 330-337 ◽  
Author(s):  
Yingjia Sun ◽  
Xinghao Ai ◽  
Jingwen Hou ◽  
Xiangyun Ye ◽  
Ruijun Liu ◽  
...  

Small-molecule marine natural products are identified to selectively recognize and stabilize the DNA-binding conformation of FOXO1, an oncogenic transcription factor.


Oncotarget ◽  
2016 ◽  
Vol 7 (43) ◽  
pp. 69760-69769 ◽  
Author(s):  
Aoli Wang ◽  
Xiao-E Yan ◽  
Hong Wu ◽  
Wenchao Wang ◽  
Chen Hu ◽  
...  

2015 ◽  
Vol 6 (22) ◽  
pp. 4541-4546 ◽  
Author(s):  
Chang Sun ◽  
Alexander T. Taguchi ◽  
Nathan J. Beal ◽  
Patrick J. O’Malley ◽  
Sergei A. Dikanov ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document